The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

• Published in: Journal of translational medicine Vol. 21; no. 1; pp. 1 - 11
• Main Authors: Mallardo, Domenico, Woodford, Rachel, Menzies, Alexander M., Zimmer, Lisa, williamson, Andrew, Ramelyte, Egle, Dimitriou, Florentia, Wicky, Alexandre, Wallace, Roslyn, Mallardo, Mario, Cortellini, Alessio, Budillon, Alfredo, Atkinson, Victoria, Sandhu, Shahneen, Olivier, Michielin, Dummer, Reinhard, Lorigan, Paul, Schadendorf, Dirk, Long, Georgina V., Simeone, Ester, Ascierto, Paolo A.
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 25.10.2023; BioMed Central; BMC
• Subjects: Analysis; Blood levels; Cancer; Care and treatment; Development and progression; Dextrose; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes therapy; Diagnosis; Drug therapy; Glucose; Health aspects; Immune checkpoint inhibitors; Immunotherapy; Ipilimumab; LDH; Medical prognosis; Melanoma; Metastases; Metastasis; Monoclonal antibodies; Multivariate analysis; Nivolumab + relatlimab; PD-1 protein; Prevention; Response rates; Risk factors; Targeted cancer therapy; Type 2 diabetes; White people; Italy

Background The combination of nivolumab + relatlimab is superior to nivolumab alone in the treatment of naive patients and has activity in PD-1 refractory melanoma. We had previously observed a reduced expression of LAG3 in melanoma tissue from patients with type 2 diabetes. Method To evaluate the i...